9780470878279

With Viagra the most famous example, drug repositioning has been growing in importance for pharmaceutical companies seeking to reinvigorate development pipelines. This book provides a broad overview of drug repositioning including the business reasons and unique opportunities and challenges. Its coverage also presents a number of current and emerging technologies that are being applied, along with relevant case studies, as well as neglected diseases to consider. Pharmaceutical researchers will learn how to use drug repositioning techniques to increase the lifespan and applications of their drugs, and also decrease both costs and development time.

Michael Barratt is an independent consultant and previously?Senior Director and Technology Platform Leader at Pfizer's Global Indications Discovery Research Unit. He has?over 15?years of experience in preclinical drug discovery research and leadership.

Donald Frail is an independent consultant and previously?Vice President of Pfizer Global Research and Development and Head of Pfizer's Global Indications Discovery Research Unit. He has over 20 years of industrial research and management experience in preclinical drug discovery and early clinical research.

Introduction
Drug Repositioning: Business Case, Strategies and Operational Considerations
Drug Repositioning: The Business Case and Current Strategies to Repurpose Shelved Candidates and Marketed
Opportunities and challenges associated with developing additional indications for clinical development candidates and marketed drugs
Clinical and operational considerations in repositioning marketed drugs and drug candidates
Regulatory considerations and strategies for drug repositioning
Application of Technology Platforms to Uncover New Indications and Repurpose Existing Drugs
Computational and Bioinformatic Strategies for Drug Repositioning
Mining scientific and clinical databases to identify novel uses for existing drugs
Predicting the polypharmacology of drugs: Identifying new uses through chemoinformatics, structural informatics and molecular modeling based approaches
Systemic phenotypic screening for novel synergistic combinations: A new paradigm for repositioning existing drugs
Phenotypic in vivo screening to identify new, unpredicted indications for existing drugs and drug candidates
Old Drugs Yield New Discoveries: Examples from the Prodrug, Chiral Switch and Site-Selective Deuteration Strategies
Academic and Non-Profit Initiatives & the Role of Alliances in the Drug Repositioning Industry
Repurposing Drugs for Tropical Diseases: Case Studies and Open-source Screening Initiatives
Drug Repositioning Efforts by Non-Profit Foundations
Repositioning Drugs for Leukemia and Lymphoma: Perspective From The Leukemia & Lymphoma Society
Repositioning drugs for Parkinson's disease: Perspective from the Michael J. Fox Foundation
Repositioning drugs for Polycystic Kidney Disease (PKD): Perspectives from the Polycystic Kidney Disease Foundation
Business Development Strategies in the Repositioning Industry
A Case Study in Drug Repositioning: Sosei
Table of Contents provided by Publisher. All Rights Reserved.

What is included with this book?

The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.

The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.

Amazon no longer offers textbook rentals. We do!

Drug Repositioning Bringing New Life to Shelved Assets and Existing Drugs

Drug Repositioning Bringing New Life to Shelved Assets and Existing Drugs

0470878274

Summary

Author Biography

Table of Contents

Supplemental Materials

Write a Review